Neurometrix, INC

NeuroMetrix, Inc. has been acquired by electroCore, Inc. through a merger completed on May 1, 2025, making NeuroMetrix a wholly-owned subsidiary of electroCore.

NeuroMetrix stockholders approved the merger agreement with electroCore at a special meeting held on March 21, 2025.

NeuroMetrix divests its DPNCheck product line assets for the Japanese market to Fukuda Denshi, securing an initial $400,000 payment and potential milestone payments up to $1.5 million.

NeuroMetrix, Inc. reports the resignation of Bradley Fluegel from the Board and Audit Committee, effective December 31, 2024, and the subsequent appointment of Joshua Horowitz to the Audit Committee.

NeuroMetrix has agreed to be acquired by electroCore, with shareholders receiving cash and contingent value rights.

NeuroMetrix's Q3 2024 results show a decline in overall revenue, primarily due to a decrease in DPNCheck sales, but also a significant increase in Quell revenue and reduced operating expenses.

NeuroMetrix's third quarter results show a significant revenue decline primarily due to changes in Medicare Advantage reimbursements, while the company continues its strategic review process.

NeuroMetrix's second quarter 2024 revenue declined significantly due to changes in Medicare Advantage reimbursements, while the company continues its strategic review to maximize shareholder value.

NeuroMetrix's Q1 2024 results show a significant revenue decline and increased net loss, alongside a strategic review and workforce reduction.

NeuroMetrix, Inc. files an amendment to its annual report on Form 10-K to include required disclosures in Part III, Items 10, 11, 12, 13 and 14, and Item 15 of Part IV.

NeuroMetrix amends its Shareholder Rights Agreement and finalizes an asset purchase agreement for its DPNCheck business in Japan, amidst an ongoing merger with electroCore.

NeuroMetrix's 2023 financial results show a significant decrease in DPNCheck revenue due to Medicare Advantage reimbursement changes, partially offset by growth in Quell sales.

Director Joshua Horowitz reports the disposal of NeuroMetrix shares due to the merger with electroCore, where shares were converted into cash and contingent value rights.

Following the merger with electroCore, NeuroMetrix director David Goodman reports the disposal of common stock and restricted stock units, receiving cash and contingent value rights in return.

Director David Van Avermaete reports the disposal of common stock and restricted stock units due to the merger between NeuroMetrix, Inc. and electroCore, Inc.

Thomas T. Higgins, CFO of NeuroMetrix, reports the disposal of common stock and restricted stock units due to the merger with electroCore, Inc.

Director Nancy E. Katz reports the disposal of common stock and restricted stock units due to the merger between NeuroMetrix and electroCore, where shares were converted into cash and contingent value rights.

Following the merger with electroCore, NeuroMetrix CEO Shai Gozani reports the disposal of common stock and restricted stock units, receiving cash and contingent value rights in return.

NeuroMetrix stockholders will vote on a proposed merger with electroCore, offering cash and contingent value rights.

NeuroMetrix has agreed to be acquired by electroCore, with shareholders receiving cash and contingent value rights.

NeuroMetrix files a supplement to its definitive proxy statement to correct errors in the security ownership information for certain beneficial owners and management.

NeuroMetrix, Inc. will hold its 2024 annual meeting of stockholders virtually on April 30, 2024, to elect two directors and ratify the appointment of Baker Tilly US, LLP as its independent registered public accounting firm.

The Radoff Family Foundation and Bradley L. Radoff have reported that they no longer beneficially own any shares of NeuroMetrix, Inc. as of June 30, 2025.